Treatment of orbital myositis with adalimumab (Humira).
Adalimumab is a fully humanized IgG1 monoclonal antibody to tumor necrosis factor-a. We describe 2 patients (17 and 13 years of age) with refractory, steroid-dependent, recurrent nonspecific orbital myositis not controlled with standard immunosuppressive medications. Both improved with adalimumab treatment, allowing reduction in corticosteroid dosage without disease flare.